Float Short %

6.52

Margin Of Safety %

Put/Call OI Ratio

0.36

EPS Next Q Diff

-0.18

EPS Last/This Y

1.06

EPS This/Next Y

0.09

Price

17.57

Target Price

24.95

Analyst Recom

1.89

Performance Q

16.82

Relative Volume

1.08

Beta

0.37

Ticker: ACAD

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2024-12-19	ACAD	16.74	0.40	16.18	27063
2024-12-20	ACAD	16.88	0.35	1.14	26218
2024-12-23	ACAD	17.2	0.55	0.09	10054
2024-12-24	ACAD	17.07	0.53	0.49	10231
2024-12-26	ACAD	17.39	0.54	1.05	10329
2024-12-27	ACAD	16.96	0.59	2.63	11673
2024-12-30	ACAD	16.71	0.59	3.96	11730
2024-12-31	ACAD	18.35	0.62	0.01	12003
2025-01-02	ACAD	18.66	0.35	0.05	17770
2025-01-03	ACAD	18.41	0.34	1.36	18425
2025-01-06	ACAD	17.46	0.37	0.82	19397
2025-01-07	ACAD	17.4	0.37	0.06	19587
2025-01-08	ACAD	17.62	0.36	0.05	19632
2025-01-09	ACAD	17.6	0.36	0.05	19632
2025-01-10	ACAD	17.25	0.36	0.28	19810
2025-01-13	ACAD	17.88	0.36	0.09	19758
2025-01-14	ACAD	16.92	0.36	0.11	19918
2025-01-15	ACAD	17.51	0.36	0.37	19939
2025-01-16	ACAD	17.52	0.36	0.08	20042
2025-01-17	ACAD	17.57	0.36	0.02	20058
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2024-12-19	ACAD	16.73	-18.7	49.3	0.71
2024-12-20	ACAD	16.88	-18.7	53.2	0.71
2024-12-23	ACAD	17.17	-24.6	55.0	0.69
2024-12-24	ACAD	17.07	-24.6	50.2	0.69
2024-12-26	ACAD	17.37	-24.6	54.9	0.69
2024-12-27	ACAD	16.96	-24.6	46.7	0.69
2024-12-30	ACAD	16.69	-24.6	48.3	0.69
2024-12-31	ACAD	18.36	-24.6	71.5	0.69
2025-01-02	ACAD	18.66	-24.6	54.7	0.69
2025-01-03	ACAD	18.39	-24.6	48.5	0.69
2025-01-06	ACAD	17.44	-24.6	41.1	0.69
2025-01-07	ACAD	17.39	-24.6	50.6	0.69
2025-01-08	ACAD	17.60	-24.6	53.8	0.69
2025-01-09	ACAD	17.60	-24.6	51.4	0.69
2025-01-10	ACAD	17.25	-24.6	47.5	0.69
2025-01-13	ACAD	17.90	-24.6	58.8	0.69
2025-01-14	ACAD	16.89	-24.6	40.2	0.69
2025-01-15	ACAD	17.51	-24.6	58.7	0.69
2025-01-16	ACAD	17.52	-24.6	51.5	0.69
2025-01-17	ACAD	17.57	-24.1	51.9	0.69
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2024-12-19	ACAD	-3.48	-4.75	6.03
2024-12-20	ACAD	-3.48	-4.75	6.03
2024-12-23	ACAD	-3.46	-4.76	6.03
2024-12-24	ACAD	-3.46	-4.76	6.03
2024-12-26	ACAD	-3.50	-4.76	5.70
2024-12-27	ACAD	-3.48	-4.76	5.70
2024-12-30	ACAD	-3.57	-4.70	5.70
2024-12-31	ACAD	-3.57	-4.70	5.70
2025-01-02	ACAD	-3.18	-4.70	5.70
2025-01-03	ACAD	-3.48	-4.70	5.70
2025-01-06	ACAD	-3.53	-4.81	5.70
2025-01-07	ACAD	-3.53	-4.81	5.70
2025-01-08	ACAD	-3.48	-4.81	5.70
2025-01-09	ACAD	-3.48	-4.81	5.70
2025-01-10	ACAD	-3.48	-4.81	5.70
2025-01-13	ACAD	-3.48	-4.87	6.52
2025-01-14	ACAD	-3.48	-4.87	6.52
2025-01-15	ACAD	-3.48	-4.87	6.52
2025-01-16	ACAD	-3.48	-4.87	6.52
2025-01-17	ACAD	-3.48	-4.87	6.52
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

0.2

Avg. EPS Est. Current Quarter

0.21

Avg. EPS Est. Next Quarter

0.02

Insider Transactions

-3.48

Institutional Transactions

-4.87

Beta

0.37

Average Sales Estimate Current Quarter

278

Average Sales Estimate Next Quarter

237

Fair Value

23.75

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

70.1

Max Drawdown 5-Year %

-77.2

Target Price

24.95

P/E

22.74

Forward P/E

23.21

PEG

P/S

3.15

P/B

5.06

P/Free Cash Flow

14.43

EPS

0.77

Average EPS Est. Cur. Y

0.69

EPS Next Y. (Est.)

0.78

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

13.83

Relative Volume

1.08

Return on Equity vs Sector %

3.2

Return on Equity vs Industry %

15.8

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.02

EBIT Estimation

51.9

ACADIA Pharmaceuticals Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 620

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

stock quote shares ACAD – ACADIA Pharmaceuticals Inc. Stock Price stock today

news today ACAD – ACADIA Pharmaceuticals Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch ACAD – ACADIA Pharmaceuticals Inc. yahoo finance google finance

stock history ACAD – ACADIA Pharmaceuticals Inc. invest stock market

stock prices ACAD premarket after hours

ticker ACAD fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: ACAD

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y